SeQuent Scientific Limited which is into Animal Health industry, and Viyash Lifesciences Private Limitd an integrated pharmaceutical company, announced that the National Company Law Tribunal (NCLT) has approved the scheme of merger between SeQuent and the Viyash group of companies.

“The NCLT approval marks the beginning of a new chapter for the combined entity and represents a fundamental transformation to leapfrog into the next orbit of the global animal health market,” SeQuent said in a statement. 

NCLT set aside insolvency plea against ZTE filed by TVS Supply Chain

“This merger not only delivers the necessary scale and capabilities for accelerating organic growth in the Animal Health market, but also provides financial resilience, stability, and management bandwidth to rejuvenate SeQuent’s inorganic growth engine,” it added. 

Dr. Haribabu Bodepudi, Founder and CEO, Viyash, said, “This merger creates the platform to deliver world-class solutions for our customers. With our strengths in R&D, custom development capabilities, manufacturing capacities, and a streamlined supply chain, we would emerge as an innovative and reliable partner for our customers across the world.”

“Over the last few months, we have developed a comprehensive plan for integration which leverages synergies for growth and capability. The momentum reflected in our recent results is only the beginning,” he said. 

Rajaram Narayanan, Managing Director and CEO, SeQuent, said, “There are significant opportunities to provide relevant, differentiated and quality care for animals.” 

“With this merger, the company will be uniquely positioned to build a world-class business and deliver on the requirements of pet owners, farmers and animal health professionals. Together, we are building a company that will set new benchmarks in quality, innovation, and customer trust,” he added.